Developing Novel Chemotherapy Delivery System
Researchers will investigate a novel nanoparticle system to deliver chemotherapy drugs directly to osteosarcoma tumors, the most common bone cancer in dogs.
Researchers will assess how well specific chemotherapy drugs work as an adjunct therapy for dogs recovering from bone cancer surgery.
This study investigates how cytogenetic changes in canine osteosarcoma affect the duration of disease-free interval when patients are treated with amputation followed by doxorubicin and non-cytotoxic suramin.
This pilot study will determine the dose and schedule of rapamycin, a promising new adjunct cancer drug.